Retinal Degeneration

30 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Retinal Degeneration
Treatment and conditionWhere it standsTrials
1.5 x 10^6 UC-MSC + CM for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
5 x 10^6 UC-MSC + CM for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AAV2-hRPE65v2,voretigene neparvovec-rzyl for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ACDN-01 for cone-rod dystrophiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ACDN-01 for stargardt diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ADVM-022 for wet macular degenerationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous iPSC-derived RPE for macular degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brinretigene Vesgedparvovec for retinal degenerationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BS01 for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eyecyte-RPE™ for geographic atrophyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
NT-101 ophthalmic solution for macular degenerationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose + OCU400 Med Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Low Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Med Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Second Eye Dosing for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU410 for geographic atrophyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OLN324 for macular degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OpRegen for geographic atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OpRegen for macular degenerationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prima for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PRIMA Bionic Vision System for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
PRIMA Products for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PRIMA Products for stargardt diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PST-611 for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Puliretgene Parvec for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
rAAV2.REP1 for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
RTx-015 for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SB-007 for stargardt diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1